Clinical Trials in Aachen, Germany
1 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled184 locationsNCT06712316
Recruiting
Phase 2
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Janssen Research & Development, LLC300 enrolled93 locationsNCT06120140
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled296 locationsNCT06380751
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
Prostate CancerNon-metastatic Castration-resistant Prostate CancerBiochemical Recurrence of Malignant Neoplasm of Prostate
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled267 locationsNCT06830720
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled140 locationsNCT05939414
Recruiting
Phase 2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals120 enrolled49 locationsNCT06465329
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
Breast Cancer (Early Breast Cancer)Advanced/Metastatic Breast Cancer
University Hospital Tuebingen13,500 enrolled61 locationsNCT02338167
Recruiting
Smoking Cessation Before Bronchoscopy or CT-guided Puncture
Pulmonary Nodule, SolitarySmoking Behaviors
RWTH Aachen University25 enrolled1 locationNCT07322796
Recruiting
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Female Breast Cancer
West German Study Group1,470 enrolled71 locationsNCT05792150
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Not Applicable
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
Limited Stage Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC600 enrolled41 locationsNCT04790253